Loading…

Bayer agreed to fully acquire Perfuse Therapeutics, a biopharmaceutical company developing PER-001 for glaucoma and diabetic retinopathy. The deal complements Bayer's ophthalmology pipeline.
“With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy.”bayer.com
Summarized from public sources; check the original articles before acting on it.